29/03/2026
Nearly 20 years of data reveal a persistent disconnect in the treatment of follicular thyroid carcinoma (FTC):
- One-third of high-risk patients don’t receive radioactive iodine (RAI) despite survival benefit
- One-third of low-risk patients receive it without clear advantage
What’s causing this gap—and how can surgeons help close it?
This ACS Bulletin Viewpoint explores the clinical, systemic, and equity implications of misaligned care and offers practical considerations for improving postoperative decision-making.
Read more:
National data show surgeons face misaligned iodine use in follicular thyroid cancer, undertreating high-risk patients and overusing therapy.